Euro23m in Third Financing Round
Milan - BioXell completed its third private financing round in October raising Euro23 million. The funding, led by the BB BIOTECH, includes NIF Ventures, Japan, and QVentures, Germany, as well as Bioxell's existing shareholders MPM Capital, Index Ventures, AlpInvest Partners, Life Science Partners and Investimenti Piccole Imprese. This financing brings the total raised to date to Euro63 million in private funds since the company was spun-out from Roche three years ago. BioXell develops compounds to treat urological and inflammatory diseases.